A Swedish observational study found lower cognitive scores in adults aged 60 to 69 were associated with higher future stroke risk, but did not prove cause.
A study from Lund University and Skåne University Hospital, published recently in the Journal of the American Heart Association, examined health data from 2001 to 2023. The research analyzed cognitive test scores to see if they were associated with later first-time stroke among older adults.
Researchers found that lower cognitive performance in adults aged 60 to 69 was associated with a significantly higher risk of future stroke. Specifically, lower overall thinking-ability scores corresponded to an 86% higher stroke risk when compared to the highest-scoring peers. Lower memory scores were associated with a 68% higher risk, and lower processing-speed scores corresponded to a 66% higher risk. The same pattern was not seen in older age groups after accounting for other health and lifestyle factors.
This research was an observational study conducted in human participants.
The research was formally titled “Lower Cognitive Function in People Aged 60 to 69 Years Is Associated With Future Stroke.” It was published in the Journal of the American Heart Association, bringing attention to the intersection of brain function and cardiovascular health. Publishing in a specialized cardiovascular journal highlights the growing focus on how neurological assessments might inform heart and vascular treatments. This overlap is a growing area of interest in modern medical research.
To evaluate how these risks were calculated, we must look at the specific group of people involved in the research. Researchers studied 4,912 adults who were enrolled in Sweden’s Good Aging in Skåne project. Participants had to be at least 60 years old to join the research effort, and the group was fairly balanced in terms of gender. Men made up 46% of the total participant pool.
A crucial element of the study design was the health status of these individuals at baseline. When they entered the study, none of the participants had a history of dementia, stroke, or transient ischemic attack. This clean baseline ensures that the initial cognitive test results were not simply reflecting the aftermath of a prior vascular event. It allowed the researchers to look forward in time to track completely new medical occurrences.
The data collection process spanned a substantial period, running continuously from 2001 to 2023. On average, participants were followed for 12.3 years after their initial assessments. During this extended follow-up window, 572 individuals experienced a first-time stroke. This long-term tracking provided the necessary volume of medical events to draw statistical comparisons.
Understanding the scope of this project is essential when analyzing longevity research and news. A large participant pool tracked over more than a decade gives researchers a deep well of observational data. However, the nature of the data dictates how the results can be applied. Observational studies can highlight important patterns, but they require careful interpretation to avoid overstating their clinical certainty.
When researchers evaluate cognitive health, they rely on multiple distinct assessments to build a complete profile. The study utilized this multifaceted approach by measuring memory, processing speed, verbal fluency, and executive function separately. By gathering data across these different areas, the team could identify which specific domains were most strongly associated with future stroke risk. The study also described an overall thinking-ability measure, which was calculated based on the available cognitive tests.
The performance on these specific domains yielded the varied risk percentages reported by the team. The highest risk association was tied to the overall thinking-ability scores. Those metrics showed an 86% higher stroke risk for the lowest performers in their 60s. Memory scores were the next strongest indicator, showing a 68% higher risk for those with the lowest results.
Finally, lower processing-speed scores were associated with a 66% higher risk of experiencing a later stroke. These figures represent relative risk comparisons, rather than absolute predictions of medical outcomes. The percentages compare the people with the lowest cognitive scores directly against the people with the highest cognitive scores in the cohort. They highlight a gap in risk between the best and worst performers, but they do not state the baseline probability of having a stroke.
The American Heart Association release reports these percentage differences clearly, but it leaves out some important statistical context. The release does not provide absolute risk differences, confidence intervals, or p-values. It also fails to list the specific covariates used in the adjustment process. This missing data means readers must view the percentages as general observational signals rather than precise medical forecasts.
The most restrictive finding in the study involves the age of the participants. The reported risk percentages only applied to individuals in the 60 to 69 age bracket. Researchers did not see the same pattern among participants ages 70 to 79 after accounting for other health and lifestyle factors. The association was also absent in participants who were 80 and older following the same statistical adjustments.
Lead author Alice Askemyr, a geriatrics researcher at Lund University and Skåne University Hospital, provided commentary on this discrepancy. She explained that the researchers separated age groups precisely because health and medication profiles can differ substantially across later life. These shifting profiles mean that a medical signal in a 65-year-old might not carry the same weight in an 85-year-old. Because of this variance, it would be misleading to describe the findings as applying uniformly to all older adults.
The data clearly shows that the correlation between cognitive scores and stroke risk shifts significantly as people age. This nuance is critical for anyone trying to interpret biology of aging and longevity science accurately. Medical guidelines must remain age-appropriate to be effective. Assuming a broad rule applies to every older demographic frequently leads to incorrect health assumptions.
The study does not establish exactly how cognitive decline might trigger a vascular event, but researchers offered a hypothesis. Askemyr suggested that lower cognition in participants in their 60s could sometimes reflect earlier, undetected brain injury. This silent damage may relate directly to future stroke risk, effectively linking the two conditions together. However, this is simply a proposed explanation, and it is not a mechanism established by the study itself.
Independent medical experts have reviewed the findings to provide context on their clinical value. Elisabeth Breese Marsh, a neurologist at Johns Hopkins who was not involved in the research, shared her interpretation. Marsh stated that the findings do not establish whether cognitive impairment itself adds to stroke risk. Instead, she noted the results may point to a possible factor for identifying people at higher risk.
Marsh’s comments underscore the difference between identifying a risk marker and proving a direct biological cause. If cognitive impairment acts merely as an indicator of poor vascular health, treating the cognitive decline directly will not prevent a stroke. The underlying vascular issues must be addressed through established medical interventions. This distinction is crucial when evaluating emerging therapeutic claims based on observational data.
Marsh also focused on the broader picture of preventative health for individuals approaching older age. She emphasized vascular-risk management and brain-health habits before older age. This is expert advice reported in the American Heart Association release, not an intervention tested by this study. It reflects the standard clinical approach to maintaining overall health over time.
This study connects cognitive performance with a later-life vascular outcome, making it relevant to healthy aging. However, the data does not show that actively improving test scores will prevent a stroke from occurring. The study concerns risk association, not a validated screening test that doctors can use immediately. The available release reports no sensitivity, specificity, or predictive accuracy.
The lack of sensitivity and specificity data in the release means the testing approach is not ready for routine clinical adoption. Without these critical metrics, doctors cannot know how many false positives or false negatives the cognitive tests might produce regarding future strokes. Until that data is established, traditional vascular risk models remain the clinical standard.
For readers, the practical takeaway involves communication rather than self-diagnosis. You should treat unexpectedly low cognitive performance as a possible reason to discuss your health with a clinician. It should not be viewed as a definitive stroke prediction or a standalone medical diagnosis. There is also no evidence that using cognitive tests to screen for stroke risk improves clinical outcomes.
Furthermore, you should never substitute cognitive testing for a standard clinical assessment of vascular risk. Understanding these limitations helps individuals navigate the complex landscape of biological age testing. By treating this research as an early observational signal, readers can avoid overreacting to minor changes in cognitive testing. True medical prevention still relies on comprehensive cardiovascular evaluations performed by licensed physicians.
The next required step is evaluating whether cognitive testing can be practically integrated into standard vascular risk assessments in clinical settings.
Evaluating whether cognitive test scores can accurately predict serious vascular events requires strictly separating observational population data from validated clinical diagnostics. AgeAmaze clarifies this persistent confusion over conflicting longevity studies, ensuring that research-minded adults can understand complex medical signals effectively. We help you navigate early clinical correlations without assuming those initial findings guarantee future medical outcomes.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
